Publications & News

Stay Up-To-Date with Prolong

November 13, 2024

Prolong Pharmaceuticals to Present Clinical Data regarding PP-007, PEGylated carboxyhemoglobin bovine product, at the 2024 International Symposium on Blood Substitutes (ISBS)

Latest

October 30, 2024

U.S. Food and Drug Administration (FDA) Grants Prolong Pharmaceuticals FDA Fast Track Designation for Novel Stroke Therapy (PP-007) in HEMERA-1 Clinical Study

Positive HEMERA-1 data pave the way for further neuroprotection trials during ‘thrombectomy era’

HEMERA‐1 CarboxyHEMoglobin OxygEn Delivery for Evascularization in Acute Stroke: A Prospective, Randomized Phase 1 Clinical Trial

October 1, 2023

Measuring And Controlling Potency Of A Targetless Biologic: Study Of Pegylated Hemoglobin

All our resources

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

October 1, 2022

Purification and Heat Inactivation of an Oxidation Prone Protein: Study of Hemoglobin

October 1, 2020

Characterization of large conjugate (PEGylated) biologics: Combination approach with CE-SDS and SEC-MALS methods

October 1, 2020

Application of Slope Spectroscopy® to the Measurement of Co-oximetry Parameters in Bovine Hemoglobin: The Case of Measuring Low Concentration Met Hemoglobin in Bovine Hemoglobin Samples

Targeting the Heme Oxygenase 1/Carbon Monoxide Pathway to Resolve Lung Hyper-Inflammation and Restore a Regulated Immune Response in Cystic Fibrosis.

Resuscitation with PEGylated carboxyhemoglobin preserves renal cortical oxygenation and improves skeletal muscle microcirculatory flow during endotoxemia

Targeting the HO-1/CO Pathway with Sanguinate: Toward Development of a Novel Anti-inflammatory Therapy for Cystic Fibrosis (CF) Lung Disease

Microvascular and Systemic Impact of Resuscitation with PEGylated Carboxyhemoglobin-Based Oxygen Carrier or Hetastarch in a Rat Model of Transient Hemorrhagic Shock.

Alternatives to Transfusion: A Case Report and Brief History of Artificial Oxygen Carriers

Artificial Blood: The History and Current Perspectives of Blood Substitutes

BNAO

September 1, 2018

52(9): 910-919 | McConachie SM, Almadrahi Z, Wahby KA, Wilhelm SM.

Pharmacotherapy in Acutely Anemic Jehovah's Witnesses: An Evidence-Based Review. Ann Pharmacother.

STROKE

May 1, 2018

38(5): 755-766 | Cipolla MJ, Linfante I, Abuchowski A, Jubin R, Chan SL.

Pharmacologically increasing collateral perfusion during acute stroke using a carboxyhemoglobin gas transfer agent (Sanguinate®) in spontaneously hypertensive rats. J Cereb Blood Flow Metab.

STROKE

April 1, 2018

27(4): 313-324 | Tallarico RT, Pizzi MA, Freeman WD.

Investigational drugs for vasospasm after subarachnoid hemorrhage. Expert Opin Investig Drugs.

OTHER

January 1, 2018

32(1) | Abu Jawdeh BG, Woodle ES, Leino AD, Brailey P, Tremblay S, Dorst T, Abdallah MH, Govil A, Byczkowski D, Misra H, Abuchowski A, Alloway RR.

A phase Ib, open-label, single arm study to assess the safety, pharmacokinetics, and impact on humoral sensitization of SANGUINATE infusion in patients with end-stage renal disease. Clin Transplant.

STROKE

December 1, 2017

27(3): 341-349 | Dhar R, Misra H, Diringer MN.

SANGUINATE® (PEGylated Carboxyhemoglobin Bovine) Improves Cerebral Blood Flow to Vulnerable Brain Regions at Risk of Delayed Cerebral Ischemia After Subarachnoid Hemorrhage. Neurocrit Care.

BNAO

August 1, 2017

27(4): 300-302 | Sam C, Desai P, Laber D, Patel A, Visweshwar N, Jaglal M.

Pegylated bovine carboxyhaemoglobin utilisation in a thrombotic thrombocytopenic purpura patient. Transfus Med.

Learn how you can be part of the journey

Join us in revolutionizing treatments for severe
and life-threatening conditions

or